CNS Response Receives Third U.S. Patent

COSTA MESA, CA--(Marketwire - March 23, 2009) - CNS Response, Inc. (OTCBB: CNSO) today announced it was awarded a patent from the U.S. Patent and Trademark Office, patent number 7,489,964, Electroencephalography Based Systems and Methods for Selecting Therapies and Predicting Outcomes, which extends application of rEEG® technology to novel methods that can expand indications for CNS pharmaceuticals. This is the third U.S. patent granted CNS Response.

“One of the most compelling opportunities in pharmaceutical marketing is the ability to expand new indications for already approved medications,” explained CNS Response CEO Len Brandt. “With the successful completion of our multisite study for the treatment of resistant depression, I believe we will have demonstrated the utility of the rEEG technology not only to physicians treating behavioral illness, but also to the pharmaceutical industry including ways described in this patent.”

Patent 7,489,964 presents novel use of CNS Response protected methodology for development of new indications of FDA approved pharmaceuticals when using an EEG computer analysis. One demonstration of patient benefit is shown in the four-year, rEEG-guided treatment of anorexia/bulimia study reported by James Greenblatt, M.D., Chief Medical Officer, Walden Behavioral Care Inpatient Psychiatry and Eating Disorder Programs. In the study of 13 severely ill, previously hospitalized patients, 13 of the 14 medications successfully used did not carry indications for eating disorders. A second patient benefit was demonstrated in study for the treatment of resistant depression by Charles DeBattista, D.M.H, M.D., Professor of Psychiatry and Behavioral Sciences, Director of Depression and Psychopharmacology Clinics, Stanford University School of Medicine, Palo Alto, Calif., where most of the patients successfully treated had regimens involving medications not indicated or traditionally used in treatment of depression.

“Both of these recent studies demonstrated that there is a significant opportunity for expansion of psychotropic indications, and that rEEG can guide that expansion,” added Brandt. “New indications for FDA approved drugs can be among the greatest return on investment for pharmaceutical companies.”

About CNS Response

Today, most physicians are able to base treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to those physicians practicing psychiatry.

CNS Response has developed a patented data-analysis capability that, with the help of a simple, non-invasive EEG, will analyze a patient’s brain waves and compare the results to an extensive patient outcomes database. The process produces an rEEG® report providing a psychiatrist with guidance to personalize a medication regimen for a patient, based on the patient’s own brain physiology. To read more about the benefits this patented technology provides physicians, patients and insurers, please visit the CNS Response website, www.cnsresponse.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.